The objectives were to determine the efficacy and safety of nasal salmon calcitonin 200 IU daily in the prevention of corticosteroid-induced osteoporosis. A minimized, double-blind, placebo-controlled trial was carried out in corticosteroid-treated patients with polymyalgia rheumatica. The setting was a tertiary care university-affiliated hospital and a total of 31 patients were enrolled. The primary outcome measure was the percentage change in bone mineral density of the lumbar spine in the two treatment groups from baseline to 1 yr of follow-up. The mean 2 .. bone mineral density of the lumbar spine in the calcitonin-treated group decreased by 1.29 2 6.76% and in the placebo group by 4.95 2 3.50% after 12 months. The observed difference of 3.65 2 2.10% between groups is statistically significant (P Q 0.05). Nasal salmon calcitonin prevented loss of bone in the lumbar spine as measured by dual-energy X-ray absorptiometry.
O is a frequent and serious side-effect of corticosteroid therapy [1] . Corticosteroids are responsible for loss of bone and resulting vertebral fractures, particularly when they are given in high doses and over prolonged periods [2] .
While the precise pathophysiology of corticosteroidinduced osteoporosis is unknown, it is clear that there is an increase in osteoclastic bone resorption and a decrease in osteoblastic bone formation [2] . Much of the early bone loss is felt to be due to increased bone resorption, while the loss of bone seen later on in therapy is probably due to reduced bone formation rates. Therapy aimed at either decreasing bone resorption with drugs such as calcitonin [3] [4] [5] [6] or increasing bone formation may prove beneficial in preventing bone loss and vertebral fractures. Given the potential for the development of these and other devastating fractures, a trial on the use of calcitonin (Miacalcin R ) in the prevention of corticosteroidinduced osteoporosis was conducted.
PATIENTS AND METHODS

Patients
Patients were potentially eligible if they had polymyalgia rheumatica (PMR) with or without temporal arthritis. A diagnosis of PMR was made if they presented with typical proximal arthralgias and myalgias, morning stiffness and a high sedimentation rate. Typically, they had an immediate reduction in these symptoms in response to corticosteroids. Patients had to be ambulatory and q50 yr of age. They had to have commenced prednisone within 1 month of study entry at a dose q10 mg/day.
Patients were excluded if they had: a prior treatment episode with prednisone of q1 month duration within the last 2 yr at doses e10 mg/day; present or previous nasal polyps or a nasal septal perforation; recent treatment (within 6 months) with drugs known to affect bone metabolism, such as bisphosphonates, sodium fluoride, oestrogen, progesterone, calcitonin, oral phosphates or pharmacological doses of vitamin D; diseases which are known to affect bone metabolism, such as hyperthyroidism, hyperparathyroidism, osteomalacia, prior malignancy; or unstable medical conditions such as uncontrolled hypertension, sarcoidosis, unstable cardiovascular disease, or insulindependent diabetes; current or prior alcohol or drug abuse; use of an investigational drug within 4 weeks and an unwillingness to maintain a daily calcium intake of 800 mg/day.
Patients were seen at baseline and followed at 1 month, 3 months, 6 months, 9 months, and finally at 1 yr. Routine biochemical measurements including serum calcium, phosphorus, alkaline phosphatase and parathyroid hormone (PTH) were performed at baseline, and at 3, 6 and 12 months. Urinary calcium and hydroxyproline levels were assessed at baseline, and at 6 and 12 months. Bone density measurements of the lumbar spine, hip and total body were also taken at baseline, and at 3, 6 and 12 months. No attempt was made to quantify physical activity levels during the study. Prednisone adjustments were carried out by the patient's rheumatologist with follow-up at the discretion of each individual rheumatologist.
Medication
Study medication was provided by Sandoz Canada Inc. Active medication consisted of salmon calcitonin nasal spray (Miacalcin R ) which delivered 100 IU/actuation, in a vehicle composed of sodium chloride, benzalkonium chloride, HCl (0.1 ) and water. The placebo was identical in appearance to active drug and consisted of inactive vehicle. Patients were allocated to calcitonin or placebo according to a minimization [7] algorithm designed to balance treatment groups simultaneously with respect to age, sex, initial bone mineral density and initial prednisone dose. Patients were instructed in the use of the nasal spray and asked to apply one puff in each nostril daily. Instructions and demonstrations were given to each patient at the start of the study and checked at each visit, to ensure proper administration of the medication. At each visit, patients were supplied with sufficient medication for each 3-month period.
All patients were provided with a calcium exchange list to allow them to determine the amount of daily calcium ingested and were counselled to achieve a dietary calcium intake of 800 mg/day. Patients who were unable or unwilling to consume adequate amounts through their diets were told that they would be allowed to use calcium supplements to bring their daily intake to 800 mg/day. Only two people were put on calcium supplements. One person in the placebo group was on 1650 mg of calcium for 15 yr prior to entering the study and was maintained on this stable dose of calcium throughout the study. A second patient in the active treatment group was commenced on 500 mg of calcium 9 months into the study by her family doctor. A formal estimate of dietary calcium was not carried out.
Bone mass measurement
Bone mineral density of the lumbar spine between the second and fourth vertebrae, the hip including the femoral neck, Ward's triangle and trochanteric region, and total body bone density were measured by dual-energy X-ray absorptiometry using a DPX scanner (Lunar Radiation Corporation, Madison, WI, USA) at baseline, and at 3, 6 and 12 months. Phantom measurements made on a weekly basis demonstrated a coefficient of variation of 0.41% and a maximum difference of 1.5%.
Serum salmon calcitonin antibodies
The assay consists of a preliminary determination of the binding capacity, in which serum is mixed with a fixed amount of labelled salmon calcitonin, allowing the formation of immune complexes. After 48 h at 4°C, the free hormone is adsorbed onto activated charcoal, separated by centrifugation, the activity of the supernatant measured and the binding capacity of the serum calculated. The magnitude of the binding capacity determines the graded amounts of salmon calcitonin used in the actual antibody titration. For this titration, a serum sample is mixed with a constant amount of labelled salmon calcitonin and increasing concentrations of unlabelled salmon calcitonin. After 48 h at 4°C, the free hormone is separated from the immune complex by adsorption onto activated charcoal and subsequent centrifugation. The activity of the supernatant is measured and the antibody index, in arbitrary units, is determined by the amount of salmon calcitonin required to displace 25% of the bound labelled salmon calcitonin from the antibody.
Analysis
The primary analysis was based on an intent-to-treat model with the percentage change from baseline in lumbar spine bone mineral density at 12 months our primary outcome. Evidence from an earlier study supported the use of calcitonin in the treatment of corticosteroid-induced osteoporosis [3] , therefore our research question (i.e. does salmon calcitonin reduce bone loss?) was directional. Given the known difficulties in recruiting patients commencing corticosteroids, we made an a priori decision to perform our primary analysis of lumbar spine bone density using a one-tailed test. All biochemical tests were analysed using a two-tailed test.
RESULTS
Demographics
There were nine females and seven males in the calcitonin group, and nine females and six males in the control group. All patients had PMR without temporal arteritis and all female patients were postmenopausal. The mean age in the calcitonin group was 71.0 2 8.4 yr and in the control group 69.8 2 7.6 yr ( Table I ). The mean dose of prednisone at study entry and follow-up was comparable between groups throughout the study (Table I) .
Biochemistry
There were no statistically significant between-group differences in baseline (Table I ) and follow-up calcium, phosphorus, alkaline phosphatase and PTH levels. PTH levels, however, appeared to be consistently, although not significantly, lower in the treatment group when compared to controls.
There were no significant differences in urine calcium or hydroxyproline levels, nor were there any significant changes in these levels throughout the study between groups. 
Bone mass measurements
Baseline bone density measurements of the lumbar spine, hip and total body were comparable between groups (Table II) . Using an intent-to-treat analysis of our primary outcome measure, the mean reduction from baseline of the lumbar spine at 12 months in the calcitonin group was 1.29 2 6.76% compared to a decline of 4.95 2 3.50% in the control group (Fig. 1) . The observed difference of 3.65 2 2.10% between groups is statistically significant (P Q 0.05). If we only include those who were on treatment at the end of the study, excluding two in the active treatment group who discontinued their medication due to adverse reactions, then the reduction in the calcitonin group is only 1.01 2 7.05%. The difference between the groups remains significant (P = 0.05). All patients in the placebo group lost bone in the lumbar spine. In the treatment group, six patients experienced an increase in bone density, while eight had a reduction. Of the eight, two had stopped treatment due to side-effects and four had developed antibodies. No statistically significant differences were noted in our secondary outcome measures: the mean change between groups in bone density, measured over a 1 yr period, of the hip including the femoral neck, trochanter and Ward's triangle, and total body bone density (Table II) .
Salmon calcitonin antibodies
Salmon calcitonin antibodies were detected in 5/14 patients at 12 months in the treatment group and none in the placebo group. Of the five patients who had antibodies present, four had a decline in bone density, while one did show an increase.
Adverse effects
There were two patients who reported adverse reactions to the study medication. One patient complained of a rash and the other of dizziness. Both were on active treatment and discontinued the study medication, but agreed to ongoing follow-up. There was one death in the active treatment group due to a myocardial infarction. Three patients were lost to follow-up, two in the placebo group and one in the active treatment group.
DISCUSSION
Our study is a minimized, double-blind, placebocontrolled trial examining the use of salmon calcitonin nasal spray in the prevention of corticosteroid-induced bone loss. Salmon calcitonin nasal spray has been used in the treatment of primary osteoporosis and has resulted in increases in bone density [8, 9] . Two known studies [5, 6] have examined the effects of salmon calcitonin nasal spray, and demonstrated its statistically significant therapeutic benefits in preventing corticosteroid-induced bone loss. In addition, two other known studies have examined the effects using the parenteral preparation of salmon calcitonin [3, 4] in the treatment of corticosteroid-induced osteoporosis.
Our study differs from many of the earlier studies in various ways. Our patients had recently commenced corticosteroid therapy and had been on it for less than a month, and therefore were unlikely to have significant corticosteroid-induced bone loss at baseline. Two out of four other studies examined subjects who had been on corticosteroids for q1 month [3, 4] , implying treatment rather than prevention. Treatment of established bone loss may explain the different results seen in the rates of change in bone density in these studies when compared to ours. The patients in these studies demonstrated incipient to severe signs of osteoporosis and already had significant bone loss at F. 1.-Lumbar spine bone density: mean percentage change from baseline.
baseline. Two other studies, in a similar manner to our study, commenced their subjects on calcitonin early in the course of prednisone therapy [5, 6] . However, one used retrospective controls, and lacked randomization and blinding, therefore weakening the validity of the study. The other study used a much higher dose of salmon calcitonin nasal spray, 400 IU/day vs 200 IU/ day in our study. The mean prednisone dose in our patient population was less than in the other studies at the time of study initiation. We obtained different results in the rates of change in bone density compared to some of these studies [3, 4] . This may be explained by the parenteral route of administration and their treatment of patients who already had established bone loss. Our study incorporated a longer follow-up period than the other studies. This may be important as bone loss due to increased bone resorption is said to occur early in those commencing corticosteroids and rates of bone loss plateau with time. Preventive interventions should, therefore, occur early as was the case in our study.
While our understanding of the pathophysiology of corticosteroid-induced osteoporosis is incomplete, it is known that there is decreased bone formation and an increase in bone resorption which, in part, is PTH mediated. Calcitonin may act to prevent this early PTH-mediated osteoclastic bone resorption. Our study confirms that corticosteroids cause increased bone loss, particularly in trabecular sites such as the lumbar spine. This loss of bone occurs early in the course of therapy and plateaus after 6 months. Losses seen at the 3 month point are similar in both the treatment and control groups. This may reflect the fact that patients had received prednisone for up to 1 month without calcitonin treatment. By 6 and 12 months, the effects of calcitonin were apparent with statistically significant differences present at 12 months. Calcitonin prevented spinal bone loss in some, but not all patients. Calcitonin antibodies did develop in five patients with four going on to have reductions in bone density. This suggests that the development of antibodies may reduce the effectiveness of therapy, as identified by Overgaard [10] . Other researchers [11, 12] recognize that the debate continues as to the most effective regimen of calcitonin. These researchers report that discontinued, low-dose calcitonin treatment may prevent the formation of antibodies and desensitization of calcitonin receptors that otherwise may account for calcitonin's ineffectiveness in some patients [11, 12] . Although these factors and their inter-relationships continue to require investigation, it may be possible to attribute the lack of response by some patients in our study to calcitonin dose levels and the continuous therapy.
Our results also suggest that there is an initial protective effect at other sites. All of the hip sites showed initial improvement, as did the total body measurement. This benefit was most noticeable within the first 6 months when rates of bone loss due to bone resorption are said to be greatest and when prednisone doses were highest. Initially, bone resorption is reduced in the calcitonin-treated group with improvement in bone mass when compared to the control group in which increased resorption continues to occur. By 6 months, bone resorption may no longer be the predominant mechanism of bone loss, but a reduction in bone formation the predominant mechanism. As a result, reductions from 3 month levels are seen in all sites for both groups. At 1 yr, the dose of prednisone had decreased to a mean of 5.38 2 3.25 mg in the calcitonin group and 5.46 2 2.97 in the placebo group. At this lower level, the effects of corticosteroids on bone are less, and in the placebo group the improvement seen in Ward's triangle and the trochanteric regions may have resulted from the reduction in prednisone dose.
Our study suggests that nasal salmon calcitonin is effective in preventing the early resorptive phase of bone loss seen when corticosteroids are commenced. Limitations of our study include a relatively small sample size due to our a priori decision to settle for a one-tailed t-test. As a result, our findings of benefit are based on a relatively small percentage of subjects who actually had an increase in bone density. Despite these findings, there appear to be many who do not respond to this dose of calcitonin; therefore, it would be important to follow those calcitonin-treated patients to ensure treatment response. More importantly, its long-term effects need to be examined further with a longer prospective study to see whether the prevention of early bone loss leads to a reduction in vertebral fracture rates.
We conclude that salmon calcitonin nasal spray in a dose of 200 IU/day prevents early bone loss in the lumbar spine in some corticosteroid-treated patients. A Dr Adachi was a Clinical Associate of the Arthritis Society at the time of the study. Sandoz Canada provided financial support, and also provided salmon calcitonin nasal spray and placebo.
